Next-Generation Psychedelics

Nasdaq-listed psychedelics biotech Enveric Biosciences (NASDAQ:ENVB) shared its financial results for the fourth quarter of 2023 and the fiscal year ended December 31, 2023, results showing: Cash in hand of $2,287,977 by December 31, 2023, as compared to the $17,723,884 held by December 31, 2022....

Clinical-stage neuroscience company Gilgamesh Pharmaceuticals has been awarded a multi-year $14 million grant from the National Institute on Drug Abuse (NIDA) to develop GM-3009, a novel, reportedly cardiac-safe ibogaine analog for the treatment of substance use disorders.  As recently...

Next-generation psychedelics biotech Cybin Inc. (NYSE: CYBN) released the full Phase 2 trial results of its deuterated psilocybin derivative CYB003 for Major Depressive Disorder (MDD.) Although a relatively small trial, outcomes for the novel psychedelic are so far showing strong treatment efficacy...

Clearmind Medicine Inc. (NASDAQ: CMND) is set to conduct a 1-for-30 reverse share split of its issued and outstanding ordinary shares, no par value, effective starting Nov. 28, 2023.  See Also: Psychedelics Capital Moves: Beckley Waves Raises $3.3M, Clearmind's $2.25M Public Offering...

Enveric Biosciences (NASDAQ: ENVB), a biopharma company developing novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders, reported its financials for Q3 2023 ended September 30, 2023, showing: Cash and cash equivalents of $4.27...

Clinical-stage psychedelics company atai Life Sciences (NASDAQ: ATAI) reported its financial results and corporate updates for the third quarter ended September 30, 2023.  In numbers: Cash, cash equivalents and short-term investments totaled $209.0 million as of Sept. 30, compared...

Clinical-stage biopharma company Reunion Neuroscience has received the FDA’s clearance on its Investigational New Drug (IND) application to begin a Phase 2 study of RE104, a novel serotonergic psychedelic compound aimed at treating postpartum depression (PPD.)  The company, which...

Israeli psychedelics biotech Clearmind Medicine (NASDAQ: CMND) has inked a research agreement with Johns Hopkins University School of Medicine (JHU) to conduct the first-in-human Phase I/IIa clinical trial on its proprietary MEAI-based compound CMND-100 for the potential treatment of Alcohol Use...

Canadian next-generation psychedelics developer Mindset Pharma (OTCMKTS: MSSTF) has entered into a definitive agreement by which Otsuka America Inc., the U.S. arm of Otsuka Pharmaceutical Co., would acquire all its outstanding shares in an all-cash transaction for approximately...

The USPTO issued a patent covering Enveric Biosciences’ (NASDAQ: ENVB) lead candidate EB-373, a psilocin prodrug under development for the treatment of anxiety disorder. Issued July 25, the new US patent gives Enveric IP rights for compositions and methods for tryptamine-derived prodrugs...

Cybin’s New US Patent Covers Proprietary Deuterated Psychedelic Analogs Clinical-stage biotech company Cybin Inc. (NYSE: CYBN) received a U.S. patent covering composition of matter claims for deuterated tryptamines, including the novel psilocybin analog in the company’s CYB003...

Next-gen psychedelics business Enveric Biosciences (NASDAQ: ENVB) reported its unaudited financial results for the second quarter of 2023 ended June 30. Results show: Cash and cash equivalents of $7.08 million, as compared to the $17.7 million held on Dec. 31, 2022. Three and six months R...

After Bright Minds Bioscience's (NASDAQ: DRUG) announcement that its quantitative EEG garnered positive results, the company stock shot up 91% Tuesday morning,  spiking to $6.18 from Monday's close of $3.23 per share. The recently-completed three-part Phase 1...

Clinical-stage psychedelics biotech Reunion Neuroscience (NASDAQ: REUN) and MPM BioImpact have completed their announced plan of arrangement for MPM’s acquisition of Reunion for approximately $13.1 million.  The company’s shareholders approved the transaction proposal at a...

As Reunion Neuroscience (NASDAQ: REUN) and Mindset Pharma (OTCMKTS: MSSTF) continue their court battle over claims on a novel 4-OH-DiPT prodrug, private biotech company Terran Biosciences has also filed a patent application over a proprietary polymorph, reported Noah Smith. 4-HO-DiPT is a...